Print Icon
 

Not displaying correctly? View in Browser

   

Newsletter

CORONAVIRUS UPDATE

THBI is actively communicating and working with elected officials, state agencies, industry partners and Texas entities to ensure the state of Texas is on the forefront of combating coronavirus, and taking proper action to keep the state safe during the global outbreak. We will be providing our partners regular updates on how our industry is responding to the epidemic. 

   

CARES Act

Coronavirus Aid, Relief, and Economic Security (CARES) Act
The CARES Act was passed by Congress on March 27, 2020 to assist business owners and nonprofits with current needs due to the COVID-19 crisis.

The U.S.Small Business Administration (SBA) and the U.S. Department of Treasury announced a robust mobilization effort of banks to provide small businesses with the capital they need. The Treasury and SBA expect to have this program up and running by April 3, 2020, so that businesses can contact a participating SBA 7(a)lender, bank, or credit union, apply for a loan, and be approved on the same day.

The CARES Act established a $349 billion SBA-backed Paycheck Protection Program (PPP) to provide immediate access to capital for small businesses who have been impacted by COVID-19. Find more information on PPP here.  

Small businesses and non-profits can get up to a $10,000 advance on an Economic Injury Disaster Loan even if a previous application was declined or still pending. For more information and to apply for the loan click here.  

The CARES Act provides financial support through a one-time check for American workers. The full credit amount ($1,200 individuals, $2,400 couples, $500 for children) is available for individuals with income at or below $75,000 ($112,500 for heads of household), and couples with income at or below $150,000. If you have children, you will receive an additional $500 per child. Your tax rebate amount will be reduced by $5 for each $100 your income exceeds the above income limits. That means for those without children, an individual will not receive any rebate if their income exceeds $99,000; and the same is true for couples with more than $198,000 of income.

You may continue to check in online at gov.texas.gov/business/coronavirus. For additional information on Texas’ response to COVID-19, visit gov.texas.gov/coronavirus.

CPRIT and COVID-19

CPRIT has made the difficult decision to suspend moving forward with the first cycle of grant applications for fiscal year 2021
CPRIT is taking this action in response to the unexpected impact to the State’s budget and a projected decrease in oil and gas revenues. CPRIT continues to evaluate releasing Requests for Applications (RFAs) for fiscal year 2021 and is committed to doing so if circumstances support it. 

CPRIT grantee and grant applicant guidance related to COVID-19
CPRIT is reviewing several issues related to COVID-19 and has provided guidance in a “frequently asked questions” format to address near-term issues that may arise over the next few months and impact grant applications, grantee reporting, and grant project timelines and costs.
   

Resource Center

Texas Workforce Commission (TWC)
At TWC, the health and well-being of our employers, employees and communities is our top priority. We understand the concern and uncertainty you may be experiencing surrounding the coronavirus (COVID-19) and are committed to being responsive to the needs of our customers.

Texas Department of State Health Services (DSHS)

DSHS is responding COVID-19 outbreak that originated in Wuhan, China. For prevention tips, symptoms, traveler information, and healthcare provider resources, see our COVID-19 website.

Centers for Disease Control and Prevention (CDC)

CDC works 24/7 to protect America from health, safety and security threats, both foreign and in the U.S. They are closely monitoring an outbreak caused COVID-19 and are the go to resource for the U.S.

Biotechnology Innovation Organization (BIO) Coronavirus Business Resource Center

As many BIO members work to develop diagnostics, vaccines and treatments to address the global COVID-19 outbreak, BIO has provided resources to help companies continue their operations with minimum disruption and keep their employees safe and healthy. 

Our Members Response

Our Industry's Role in Solving the Crisis  
The biotech industry is helping lead the fight against the coronavirus. BIO is working closely with government agencies and others in our industry to ensure resources are available to develop responses to COVID-19 and to get diagnostics, therapies and vaccines to patients as quickly and safely as possible

Amgen And Adaptive Biotechnologies announce strategic partnership to develop a therapeutic to prevent or treat COVID-19
The mutually exclusive collaboration brings together Adaptive's proprietary immune medicine platform for the identification of virus-neutralizing antibodies with Amgen's expertise in immunology and novel antibody therapy development. 

Bayer announced a donation of one million products including over-the-counter medications and multivitamins
As a part of the company’s sustainability strategy, Bayer committed to expand access to everyday health for 100 million people in under served communities around the world by 2030. This donation is a key step in the company’s plan to help enable health for all.

CureDuchenne has announced new partnership with Dyne Therapeutics, an innovative organization whose FORCE™ Platform is working to bring transformational therapies for serious muscle diseases

CureDuchenne understands the difficult financial and health-related decisions these times present for many organizations. They are still investing, caring and battling on behalf of the Duchenne community. As we push through this coronavirus crisis, and when it passes, our loved ones will still have CureDuchenne’s unwavering commitment to funding impactful research.

Trauma Insights, a San Antonio-based contract research organization that partners with biotech companies to develop medical technologies relevant to the military and national security, announces two new partnerships 

Trauma Insights will partner with Cellenkos, Inc. to develop CK0802 for the treatment of COVID-19 Mediated Acute Respiratory Distress Syndrome (CoVARDS). Read more


Trauma Insights will partner with Heat Biologics, Inc. to support the development of a vaccine that leverages Heat's proprietary gp96 platform designed to target the SARS-CoV-2 coronavirus that causes COVID-19.Read more. 

Become a THBI Member

THBI is the Texas policy voice for the healthcare and bioscience industry. With a focus on advocacy, public policy and industry vitalization, THBI works with government and industry leaders to enhance and further establish the life sciences in Texas, and to promote effective legislation at the state and federal level. 

There is no better time to join the conversation and become a member of THBI. Our members are on the forefront of collaboration and the research and development of vaccines, therapeutics and diagnostics to combat COVID-19. No matter the size of your company or level of involvement, your participation at the table is important. To learn more about membership opportunities, email julia@thbi.com. 

BIO Busuiness Solutions

As the world has been dealing with the implications of the COVID-19 pandemic, BIO has been working with partners and member companies on business continuity, mitigation and contingency planning. As part of BIO Business Solutions Cost Savings Program, we have several benefits to help you run your business, access resources and reduce spending.

To become a THBI member and gain access to the BIO Business Solutions purchasing program, email julia@thbi.com.

Stay Connected

THBI has published a COVID-19 page on www.thbi.com for helpful resources and an archive of the THBI COVID-19 email updates. 
   
Copyright © 2020 THBI. All rights reserved.

Our mailing address is:
807 Brazos Street, Suite 607Austin, TX 78701

This message is sent to you because your email address is on our subscribers list. If you are not interested in receiving more emails like this one, click here to unsubscribe.